Drugmaker Piramal Healthcare has agreed to buy a U.S.-based healthcare data provider for $635 million to boost research and development, the company said on Wednesday, a month after it acquired the ne

Dugmaker Piramal Healthcare sees revenue potential of $1.5 billion from its new florbetaben molecule, a possible Alzheimer's treatment acquired by the company in a deal with Germany's Bayer AG.